Literature DB >> 15330131

Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting.

Vincenzo Puro1, Stefania Cicalini, Gabriella De Carli, Fabio Soldani, Francisco Antunes, Ulla Balslev, Josip Begovac, Enos Bernasconi, José L Boaventura, Magda Campins Martí, Rok Civljak, Barry Evans, Patrick Francioli, Fiona Genasi, Christine Larsen, Florence Lot, Suzanne Lunding, Ulrich Marcus, Alvaro A Pereira, Tania Thomas, Slavko Schonwald, Giuseppe Ippolito.   

Abstract

The European Commission funded a project for the standardisation of the management of occupational exposures to HIV/blood-borne infections and antiretroviral post-exposure prophylaxis (PEP) in Europe. Within this project, the following recommendations and rationale were formulated by experts representative of participating countries. Based on assessment of the exposure, material, and source characteristics, PEP should be started as soon as possible with any triple combination of antiretrovirals approved for the treatment of HIV-infected patients; initiation is discouraged after 72 hours Rapid HIV testing of the source could reduce inappropriate PEP. HIV testing should be performed at baseline, 4, 12, and 24 weeks, with additional clinical and laboratory monitoring of adverse reactions and potential toxicity at week 1 and 2. HIV resistance tests in the source and direct virus assays in the exposed HCW are not recommended routinely. These easy-to-use recommendations seek to maximise PEP effect while minimising its toxicity and inappropriate use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330131     DOI: 10.1023/b:ejep.0000032349.57057.8a

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  47 in total

Review 1.  Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries.

Authors:  D Rey; M K Bendiane; J P Moatti; K Wellings; R Danziger; W MacDowall
Journal:  AIDS Care       Date:  2000-12

2.  Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures.

Authors:  P C Tack; J W Bremer; A A Harris; A L Landay; H A Kessler; D R Kuritzkes
Journal:  JAMA       Date:  1999 Mar 24-31       Impact factor: 56.272

3.  HIV postexposure prophylaxis. German-Austrian recommendations. Deutsche AIDS-Gesellschaft (DAIG) and Osterreichische AIDS- Gesellschaft (OAG).

Authors:  H Brodt
Journal:  Eur J Med Res       Date:  1998-10-14       Impact factor: 2.175

4.  Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-01-05       Impact factor: 17.586

5.  Emergency department management of occupational exposures: cost analysis of rapid HIV test.

Authors:  J C Kallenborn; T G Price; R Carrico; A B Davidson
Journal:  Infect Control Hosp Epidemiol       Date:  2001-05       Impact factor: 3.254

6.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 7.  Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood.

Authors:  L A Pinto; A L Landay; J A Berzofsky; H A Kessler; G M Shearer
Journal:  Am J Med       Date:  1997-05-19       Impact factor: 4.965

Review 8.  Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure.

Authors:  M P Busch; G A Satten
Journal:  Am J Med       Date:  1997-05-19       Impact factor: 4.965

Review 9.  Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview.

Authors:  D M Bell
Journal:  Am J Med       Date:  1997-05-19       Impact factor: 4.965

10.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

View more
  4 in total

1.  An update on HIV related epidemiological research.

Authors:  Nicole H T M Dukers; Maria Prins; Roel A Coutinho
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 2.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  The management of needlestick injuries.

Authors:  Heiko Himmelreich; Holger F Rabenau; Matthias Rindermann; Christoph Stephan; Markus Bickel; Ingo Marzi; Sabine Wicker
Journal:  Dtsch Arztebl Int       Date:  2013-02-01       Impact factor: 5.594

Review 4.  The importance of implementing safe sharps practices in the laboratory setting in Europe.

Authors:  Gabriella De Carli; Dominique Abiteboul; Vincenzo Puro
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.